Latex device labeling
This article was originally published in The Gray Sheet
Combination products currently regulated under human drug or biologic labeling will not be subject to provisions of FDA's final rule requiring label statements for all medical devices that contain or have packaging that contain natural rubber that contacts humans, the agency says in a May 6 Federal Register notice. FDA "intends to initiate a proceeding to propose natural rubber labeling requirements for drugs and biologics, including combination products that are currently regulated under drug or biologic labeling provisions," the agency states in the notice, which is issued as an "interpretation" of its Sept. 30, 1997 final regulation on user labeling for medical devices containing natural rubber ("The Gray Sheet" Oct. 6, 1997, p. 3)...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.